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Ethical and juridical issues have recently been raised in Italy regarding experimental stem cell
therapy (Stamina), which was authorized but then stopped after it was administered to a wide
range of patients as a compassionate treatment for neurodegenerative diseases (Carrozzi et al., 2012;
Finkel, 2012; Mercuri and Bertini, 2012; Abbott, 2013; Cattaneo and D’Ambrosio-Lettieri, 2015).
Research in the field of somatic stem cells isolated from adult organs has been developed over the
last few decades as a powerful tool in regenerative medicine. In particular, most experimental tissue
regenerative applications are based on the use of mesenchymal stem cells (MSCs) to regenerate
damaged tissues (Biffi et al., 2013). Some have claimed that MSCs could be capable of neuronal
transdifferentiation, though this feature is poorly substantiated and widely contested (Brundin
et al., 2010; Dyson and Barker, 2011; Lattanzi et al., 2011; Bianco et al., 2013; Urbán and Guillemot,
2014; van Velthoven et al., 2014).
Despite the fact that numerous ongoing studies and clinical trials have exploited such stem
cells in the treatment of bone and soft tissue defects, no studies have investigated their possible
application in the field of degenerative diseases affecting non-mesodermal organs. Hence, yielding
promising results could produce higher expectations in poor prognosis patients and in their
caregivers (Notarangelo, 2013; Campana et al., 2014; Reddington et al., 2014).
The complicated sequence of events of the so-called “Stamina” method has garnered keen public
support, but equally, scientists’ opposition. This has generated a long and complex investigation by
the Public Prosecutor’s office in Turin regarding accusations of criminal conspiracy aimed at fraud,
unlawful medical practice, violation of privacy norms and many other crimes.
No details of these innovative protocols have been provided by the promoters of this method,
who generically claimed that they were able to differentiate bone marrowMSCs into nerve cells for
the treatment of neurological, genetic, and autoimmune diseases. The principles of these studies
seem to derive from two Russian and Ukranian papers (Schegel’skaya et al., 2003; Yavorskaya et al.,
2006). Only very recently, the results obtained in three patients have been described, although the
description of the experimental protocol is still inadequate (Villanova and Bach, 2015).
However, this story finally caused the Public Health System to be involved in a legal dispute,
as the method was claimed to represent a compassionate treatment, for which unlimited access
should be granted. A compassionate therapy is administered when there is no alternative to the
experimental therapy—in the broadest sense of the term, with the relevant variables—even in order
to grant the patient and their relatives a dignified co-existence with a pathological condition which
would otherwise be progressive, irreversible and lethal.
Indeed the protection of the right to health is attributed to the legislator even in deciding
the financial allocation of taxpayers’ funds so this right remains dependent on the choice of
instruments, timing and implementation methods as foreseen by the law and by the administrative
authorities. As a consequence, the access to a new therapy, even administered with a compassionate
aim, as a matter of principle cannot be deemed individually unlimited, because it is regulated by
healthcare norms that define the prerequisites of scientific validity and the “ethicalness” of the new
therapy, including stem cells.
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A solid and efficient regulatory framework is required in
Europe as the milestone for developing cell-based therapies
(Blasimme and Rial-Sebbag, 2013). This is particularly true for
the compassionate therapies in which the European Medicines
Agency (EMA)—in the Guidelines on Compassionate Use of
Medicinal Products [pursuant to article 83 of Regulation (Ec) no
726/2004]—states that it is only possible to collect data on safety
during compassionate programmes but such programmes cannot
replace clinical trials that provide essential information relative to
the benefit/risk balance of a medicinal product.
In the light of this, it is still not clear on what scientific
bases the unknown Stamina Method was authorized by the Ethic
Committee at the Spedali Civili in Brescia, despite the fact that the
quite alarming results of the inspection carried out by the Italian
Medicine Agency—AIFA (a body entitled to grant access to drugs
and to supervise the correct and safe use of drugs)—prohibited
any immediate and effective sample taking, transport, handling,
cultures, stocking, and administering of human cells at the “Spedali
Civili” hospital in Brescia promoted by the Stamina Foundation.
The Regional Administrative Court (TAR) of Brescia (9th
of September 2012) confirmed the “lack of scientific evidence,”
the omitted transmission of the data to the Italian National
Institute of Health and the absence of valid opinions of the Ethics
Committee for each of the treated patients.
However, in the uneasy pondering of the interests at stake—
on the one hand patients’ interest in continuing the so-called
compassionate therapy inhibited by AIFA, on the other the power
of this agency to regulate the experimentation of new drugs—
the TAR considered decisive the unlikelihood of getting to know
the production method and the therapeutic use of mesenchymal
cells used by “Stamina” which, moreover, is not acknowledged to
be valid by the national and international scientific community.
Therefore, the only way of continuing the therapies was
through the implementation of adequate judiciary measures.
This led to a proliferation of urgent appeals to the Labor
Law Judge, who has jurisdiction over matters of mandatory
medical assistance; but these appeals were aimed at obtaining
from the hospital in a compulsory way the administration of
stem cells without any proven therapeutic efficacy, thus causing
the irreparable violation of the primary and constitutionally
guaranteed right to health and life of the patients affected by
terminal pathologies and/or negative prognoses.
The complex legal framework has not even been solved by the
approval of Law Decree n. 24/2013, converted with modifications
by Law n. 57/2013. This law—because of the deep anguish of
the patients, who hope to obtain from the Stamina therapy those
benefits in terms of health which, because of the serious [nature
of the] diseases under discussion, cannot be provided by the use of
already approved drugs or at least already experimented drugs and
because of the absence of serious side effects—allowed only for
the continuation, under the National Health Service conditions,
of the stem cell therapies.
In opposition to the judges’ authorization, imposing
the injections, two independent scientific committees were
appointed by the Minister. They expressed their negative
opinion because the Stamina method for the preparation of MSCs
is not adequate. The MSCs produced with the Stamina method
do not satisfy the requirements for the definition of these cells
as therapeutic agents. The proposed Stamina protocols do not
satisfy the basic requirements for any clinical experimentation
because the Stamina method and control do not possess the
scientific requisites necessary to carry out a clinical trial, including
the evaluation of the safety and effectiveness [and therefore] the
conditions to begin the experimentation with the so-called Stamina
method, in particular the patients’ safety, do not exist. The Health
Ministry, consequently, with a note dated 4 November 2014, has
acknowledged that the experimentation [. . . ] cannot be continued
further.
The role of the Courts in ordering the physicians to
provide the experimental treatment, especially to a vulnerable
population, was largely criticized by the scientific community
(Finkel, 2012). In comparison with the proclaimed results of
the Stamina method, other scientists began a compassionate
therapy, administering intrathecal MSCs in children with Type
I spinal muscular atrophy (SMA). Because of the lack of efficacy
the Hospital, in accordance with the local Ethical Committee,
stopped the recruitment of patients for this kind of therapy
(Carrozzi et al., 2012). The scientists highlighted the risk that
the combination of newspaper hype and parental hope, with the
support of the Courts that are sympathetic to families with children
with severe disorders,may produce a lack of scientific evidence in
conflict with the common rules of clinical investigation.
From this perspective, one can notice a significant similarity
with what often happens in cases regarding the side effects of
vaccines, which have generated several different rulings on the
unidentifiable nature of the damage most likely to be seen in a
causal correlation with the administration of the vaccine.
In both hypotheses, what “recedes” in the face of a health or a
life threat are not only the legislative and administrative powers
to allocate—limited—resources for health matters, imposing
certain services and prohibiting others, but also the scientific
validity of the treatments themselves, which constitutes the
ineluctable rational requirement for the exercise of that power.
Each time science does not give univocal answers—which
means almost always in medicine—the lack of access to
compassionate treatments may lead to an irreparable violation
of the right to health and to human dignity. This is true for
the administration of whatever drug may have even a vague
and controversial chance of success or even just palliative effects
(in other words, imposing an indemnification in the case of
pathologies whose correlation with vaccines may be possible but
not demonstrable).
Therefore, the judge in these cases does not invent science:
s/he simply disregards it.
This approach may be debatable and it has recently been
disregarded by the Italian Constitutional Court (274/14),
which recalled that the decisions regarding therapeutic choices,
specifically addressing their adequacy, cannot arise from the
politically discretional evaluations of the legislator, but must be
founded on the verification of the state of scientific knowledge
and the experimental evidence acquired by institutions and
bodies—usually national and supranational—in charge of doing
so, considering the essential matter with which the technical-
scientific bodies deal.
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Based on these preconditions, the judge affirmed that the
clinical experimentation of a new drug does not normally allow
charging in advance the public bodies with the duty to administer
the drug either for the need to safeguard health or for the need
to guarantee the correct allocation of funds available from the
National Health Service.
As a consequence, the continuation of the therapies with the
Stamina method establishes a waiver, due to its nature as an
exception, which does not set up any irrational disparity in the
treatment for those patients who ask for access to compassionate
therapies which are no longer allowed because they lack an
adequate technical-scientific support.
In the same way, the European Court of Human Rights
(Durisotto v. Italy—application no. 62804/13) has ruled that the
prohibition on access to the therapy, imposed by an Italian court
in application of legislative decree no. 24/2013, did not violate any
human right because it pursued the legitimate aim of protecting
health, was proportionate to that aim and was neither arbitrary
nor discriminatory.
If not even the judges can disregard science, certainly doctors
cannot disregard it.
It is a fact that stem cell treatment is used in certain human
conditions; however physicians who prescribe and administer the
new treatment need to understand the basic principles of this
study. In the Stamina method we firstly have to ask how bone
marrow cells can be converted into nerve cells or can promote
blood vessel growth.
So, which norm applies to this case, since we have a judiciary
measure which, hypothesizing, conflicts with the obligations of
diagnostic therapeutic autonomy and responsibility established by
the latest edition (2014) of the Italian Code ofMedical Ethics (art.
22 the doctor whom one asks for services which are in conflict with
their conscience or with their clinical convictions can deny his/her
services unless this behavior is a serious or immediate threat to
the health of the patient, and must provide citizens with all useful
information and clarification)?
The prosecutor’s investigation revealed that the doctors who
were injecting the product in the patients did not appear to
be aware of the real nature of the biological material that was
being administered. Should the doctors at the “Spedali Civili”
in Brescia, who have declared to the special commissioner of
the hospital their refusal to administer the Stamina imposed by
judicial measures, be subject to penal sanctions for nonfeasance
(art. 328 penal code: the person in charge of a public service
who wrongfully denies the service of which they are in charge,
and which, for judicial, public safety, public order or hygiene or
health reasons must be performed without delay, is sanctioned
with imprisonment for a period of 6 months to 2 years)?
The answer, in our opinion, must be negative. And this is
because in these cases the refusal cannot be considered wrongful,
but, on the contrary, is founded on a due justification in one’s
professional field as well as on the law and on the regulations of
the appropriate body (AIFA).
The history of this new “sensational” treatment ended with the
head of the project negotiating a plea bargain.
Concluding Remarks
In short, the improvement of stem cell experimental therapy
needs rigid juridical rather than scientific boundaries. Scientists
have a fundamental role in communicating the aims coupled
with the limitations of their ongoing studies. This means that the
usefulness of stem cells can be affirmed with caution, especially
in the case of compassionate therapies, strictly following the
guidelines imposed by the regulatory authority. The judges
have the great responsibility to agree with the best scientific
evidence without imposing their own “personal” interpretation
of science simply to meet the social expectations of poor
prognosis patients and of their caregivers. Moreover, they
must punish the defendants who make false claims about a
given therapy, playing on patients’ vulnerabilities. Many of
these sensational therapies hide economic interests that are
“paid for” by the patients and the community as a whole.
The politicians have the institutional function not to ride
the wave of the moment but to guarantee the constitutional
right of each patient to make their own healthcare decisions
based upon solid scientific findings. Finally doctors may help
patients to understand the meaning of compassionate therapy
that can never be separate from scientific methodology and
evidence.
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